ES2045120T3 - Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria. - Google Patents

Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.

Info

Publication number
ES2045120T3
ES2045120T3 ES88305450T ES88305450T ES2045120T3 ES 2045120 T3 ES2045120 T3 ES 2045120T3 ES 88305450 T ES88305450 T ES 88305450T ES 88305450 T ES88305450 T ES 88305450T ES 2045120 T3 ES2045120 T3 ES 2045120T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
loss
memory
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88305450T
Other languages
English (en)
Other versions
ES2045120T4 (es
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Efamol Holdings PLC
Original Assignee
Efamol Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Holdings PLC filed Critical Efamol Holdings PLC
Application granted granted Critical
Publication of ES2045120T3 publication Critical patent/ES2045120T3/es
Publication of ES2045120T4 publication Critical patent/ES2045120T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

TRATAMIENTO O PREVENCION DE LA PERDIDA DE MEMORIA CON UN MEDICAMENTO QUE CONSISTE EN UN ACIDO GRASO ESENCIAL N-B SELECCINADO DE GLA, DGLA, AA, ACIDO ADRENICO Y EL ACIDO 22:5 N-6 Y UN ACIDO GRASO ESENCIAL Y EL ACIDO 22:5 N-6 Y UN ACIDO GRASO ESENCIAL N-3 SELECICONADO DE LOS ACIDOS 18:4 N-3 Y 20:4 N-3, EPA, EL ACIDO 22:5 N-3 Y DMA.
ES88305450T 1987-06-24 1988-06-15 Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria. Expired - Lifetime ES2045120T4 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878714772A GB8714772D0 (en) 1987-06-24 1987-06-24 Essential fatty acid compositions

Publications (2)

Publication Number Publication Date
ES2045120T3 true ES2045120T3 (es) 1994-01-16
ES2045120T4 ES2045120T4 (es) 1996-07-16

Family

ID=10619463

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88305450T Expired - Lifetime ES2045120T4 (es) 1987-06-24 1988-06-15 Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.

Country Status (13)

Country Link
EP (1) EP0296751B1 (es)
JP (1) JPH0788301B2 (es)
KR (1) KR960010832B1 (es)
AT (1) ATE81453T1 (es)
AU (1) AU608012B2 (es)
CA (1) CA1310911C (es)
DE (1) DE3875286T2 (es)
ES (1) ES2045120T4 (es)
GB (1) GB8714772D0 (es)
GR (1) GR3006403T3 (es)
HK (1) HK158496A (es)
IE (1) IE63386B1 (es)
ZA (1) ZA884484B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
EP1092352A3 (en) * 1991-01-24 2003-08-27 Martek Corporation Microbial oil mixtures and uses thereof
US5262162A (en) * 1991-09-06 1993-11-16 Merz & Co. Gmbh & Co. Cerebral-activating extract
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JPH07122071B2 (ja) * 1993-02-23 1995-12-25 工業技術院長 オクタデカテトラエン酸を構成成分として含有する物質の製造方法
ATE185949T1 (de) * 1995-07-28 1999-11-15 Herbert Schlachter Zwei-phasen-präparat
US6403349B1 (en) * 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
US20030163845A1 (en) 1998-09-02 2003-08-28 Pradip Mukerji Elongase genes and uses thereof
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US6913916B1 (en) 1998-09-02 2005-07-05 Abbott Laboratories Elongase genes and uses thereof
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7070970B2 (en) 1999-08-23 2006-07-04 Abbott Laboratories Elongase genes and uses thereof
DK1254238T3 (da) * 2000-02-09 2009-11-30 Basf Se Nyt elongasegen og fremgangsmåde til fremstilling af flerumættede fedtsyrer
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
JP5496163B2 (ja) * 2011-10-19 2014-05-21 サントリーホールディングス株式会社 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2014141437A (ja) * 2013-01-24 2014-08-07 Oriza Yuka Kk 学習記憶改善剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US4851431A (en) * 1986-11-26 1989-07-25 Bar Ilan University Physiologically active and nutritional composition

Also Published As

Publication number Publication date
GB8714772D0 (en) 1987-07-29
KR890000085A (ko) 1989-03-11
ZA884484B (en) 1989-03-29
EP0296751B1 (en) 1992-10-14
KR960010832B1 (ko) 1996-08-09
JPH0788301B2 (ja) 1995-09-27
ES2045120T4 (es) 1996-07-16
JPS6422819A (en) 1989-01-25
DE3875286T2 (de) 1993-03-11
AU1821888A (en) 1989-01-05
AU608012B2 (en) 1991-03-21
HK158496A (en) 1996-08-30
CA1310911C (en) 1992-12-01
EP0296751A1 (en) 1988-12-28
IE881828L (en) 1988-12-24
IE63386B1 (en) 1995-04-19
GR3006403T3 (es) 1993-06-21
DE3875286D1 (de) 1992-11-19
ATE81453T1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
ES2045120T4 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
HK37694A (en) Fatty acids compositions
GR3025898T3 (en) Use of fatty acids for increasing gut calcium absorption
ES2107622T3 (es) Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal.
NO912151D0 (no) Essensiell-fettsyre-behandling.
ES2060290T3 (es) Composiciones de acidos grasos esenciales (efa) y terapia.
ES2061650T3 (es) Composiciones para el tratamiento de la enfermedad periodontal.
OA06930A (fr) Procédé de préparation d'acides aza-bicyclo-octane carboxyliques.
DE3366506D1 (en) Pharmaceutical composition
NO912545D0 (no) Nye 3,3'-ditobis (propionsyrer) og estere derav samt fremgangsmaate for dens fremstilling.
EP0302481A3 (en) Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
ES2082390T3 (es) Acido gamma-linolenico para la preparacion de un medicamento para impedir la reoclusion de las arterias.
EP0211502A3 (en) Use of metabolites of linoleic or linolenic acid in the treatment of premenstrual syndrome
ATE19855T1 (de) Pharmazeutische und diaetetische zusammensetzung.
ES511645A0 (es) "metodo y aparato para el control automatico de la longitud de una hilera de articulos a moldear por inyeccion".
NO903994D0 (no) Fremgangsmaate for fremstilling av 5-aroyl-1,2-dihydro-3h-pyrrolo-(1,2-a)-pyrrol-1-carboxylsyrer og alkylestere og salter derav.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 296751

Country of ref document: ES

FG2A Definitive protection

Ref document number: 0296751

Country of ref document: ES